

# Updated analysis by Mangold Insight

Today, Mangold Insight published an updated company analysis of Lumito.

The company analysis in a commissioned analysis and is available [here](#), but can also be accessed from Lumito's website [here](#).

Please note that the company analysis is in Swedish.

## For further information, please contact:

Mattias Lundin, CEO Lumito

E-mail: [ml@lumito.se](mailto:ml@lumito.se)

Ph: +46 76 868 45 09

[www.lumito.se/en](http://www.lumito.se/en)

**Lumito** specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off from a research group at the Department of Atomic Physics and Laser Centre. [www.lumito.se/en](http://www.lumito.se/en)

The share is traded on NGM Nordic SME, under the name LUMITO. Mangold Fondkommission AB is Lumito's Mentor.